The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, ...

S&P 500, Dow Jones Industrial Average, Chevron Corp, Cisco Systems Inc. Read Contrarian Outlook (Brett Owens)'s latest ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair, have the potential to generate significant revenues for Merck over the long ...

Merck MRK also markets two PCV vaccines — Capvaxive and Vaxneuvance. MRK received FDA approval for Vaxneuvance in 2021 for 15 serotypes in older adults. Merck generated $647 million from ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

Merck & Co., Inc. (NYSE ... (up 6% to $1.5 billion), and contributions from new products like Winrevair and Capvaxive. The stock currently has a consensus Moderate Buy rating from analysts.

Merck & Co., Inc. (NYSE ... (up 6% to $1.5 billion), and contributions from new products like Winrevair and Capvaxive. The stock currently has a consensus Moderate Buy rating from analysts.